FTSE 100 Dips as GSK Shares Fall Post-Nuvalent Deal

FTSE Futures Updates

The UK’s blue-chip index, FTSE 100, experienced a decline on Tuesday, primarily influenced by the performance of GSK. This movement followed the healthcare company’s announcement regarding its intention to acquire shares of U.S.-based drug developer Nuvalent for $10.6 billion, a strategic move aimed at enhancing its lung cancer treatment portfolio.

The blue-chip FTSE 100 index slipped 0.3% to 10,341 points by 0810, while the midcap FTSE 250 edged up 0.2%.

  • Shares of GSK declined by 2.8%, contributing to a broader downturn in the FTSE 350 Pharmaceuticals and Biotechnology index, which fell by 1.6%, marking it as the largest sectoral decliner.
  • Global markets were observing indications of de-escalation in the Middle East, as Iran and Israel announced a cessation of hostilities following an appeal from U.S. President Donald Trump, who also suggested that he might have “an idea” for an Iran deal in the near future.
  • Concerns regarding inflation, driven by increased energy costs resulting from the ongoing conflict, have led investors to anticipate a 25 basis point interest rate increase by the Bank of England in September, as indicated by data.
  • The primary FTSE indexes have lagged behind their counterparts in Asia and the U.S., attributable to their limited engagement with AI stocks. Against this backdrop, Britain set out a new £1.1 billion plan to build domestic AI computing capacity.
  • Among other stocks, BP slipped 1%, tracking a slip in crude prices. Attention on the company has intensified following the dismissal of former chair Albert Manifold, with a recent report indicating that investors and former executives at the oil major were unaware of the specific circumstances surrounding his exit.
  • Venture Capital firm Molten Ventures experienced a 9.5% increase following the release of its annual results.
  • Similarly, Fever-Tree Drinks saw a 6.4% rise after the carbonated mixer supplier expressed confidence in meeting full-year market expectations for revenue and core profit, alongside announcing an increase in share buybacks.
  • Homebuilder MJ Gleeson opens new tab lost 3.5% after projecting annual adjusted pretax profit below market expectations.